53
Participants
Start Date
December 30, 2015
Primary Completion Date
June 7, 2019
Study Completion Date
June 7, 2019
OBIZUR
Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
University of Pennsylvania Health System, Philadelphia
Comprehensive Cancer Center of Wake Forest Unversity, Winston-Salem
Duke University Medical Center, Durham
Emory University School of Medicine, Atlanta
University of Florida, Gainesville
Cleveland Clinic, Cleveland
Indiana Hemophilia and Thrombosis Center, Indianapolis
Henry Ford Health System, Detroit
Michigan State University, East Lansing
University of Iowa Hospitals & Clinics, Iowa City
Blood Center of Southeast Wisconsin, Milwaukee
Bleeding and Clotting Disorders Institute, Peoria
Washington University, St Louis
Tulane University Hospital & Clinics, New Orleans
University of Colorado Health, Aurora
University of Utah Health Sciences Center, Salt Lake City
Baxalta Innovations GmbH, now part of Shire
INDUSTRY
Baxalta now part of Shire
INDUSTRY